Humacyte, Inc. 8-K

What Happened
Humacyte, Inc. (HUMA) filed a Form 8-K on March 19, 2026 reporting preliminary operational and financial information for the year ended December 31, 2025. The filing (Item 2.02) incorporates the disclosure titled "Operational Updates--Preliminary Financial Information for the Year Ended December 31, 2025" that appears under Item 8.01 (Other Events). The 8-K also includes an investor presentation and an update to the company’s risk factors as exhibits.

Key Details

• Filing date: March 19, 2026 (Form 8-K).
• Period covered: Preliminary financial information for the year ended December 31, 2025 (reported under Item 2.02 via incorporation of Item 8.01 disclosure).
• Exhibits filed: 99.1 — Humacyte Investor Presentation (March 2026); 99.2 — Risk Factor Updates (dated March 19, 2026); plus the Inline XBRL cover page file (104).
• The 8-K does not announce any executive changes, mergers, or bankruptcies (no Item 5.02, 1.01, or 1.03 disclosures in this filing).

Why It Matters
This filing signals Humacyte has updated investors with preliminary year-end results and refreshed risk disclosures — material information investors should review before making decisions. Retail investors should read the attached investor presentation and the risk factor updates to see the company’s reported earnings/revenue trends, any changes to risk profile, and implications for cash runway or guidance. The filing itself incorporates those materials by reference; the exhibits contain the detailed figures and narrative.